Syncona up on drug approval – on Wednesday 23 May, Syncona announced that Blue Earth Diagnostics had received confirmation of approval of its product AxuminT (fluciclovine (18F)) (“Axumin”) by the European Commission. This follows the announcement on 24 March 2017 that the Committee for Medicinal Products for Human Use had made a positive recommendation for Axumin to be granted marketing authorisation The approval means that Axumin is now authorised to be sold in all European Union member states as well as Iceland, Liechtenstein and Norway. Axumin will initially be commercially available in Norway, with roll-out to additional countries planned in 2018.Syncona holds a 90 per cent interest in the share capital of Blue Earth Diagnostics.
Syncona’s share price rose from 153p to 160p on the back of this news.
SYNC : Syncona up on drug approval